TOBIRA THERAPEUTICS INC

Inactive Instrument

Tobira Therapeutics Inc Share Price Nasdaq

Equities

US75874Q1076

Biotechnology & Medical Research

Chart Tobira Therapeutics Inc

Duration

Period

Style

Press releases Tobira Therapeutics Inc

Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16	BU
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16	BU
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16	BU
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16	PU
Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin	12/09/16	BU

More press releases

News in other languages on Tobira Therapeutics Inc

TOBIRA fait gagner plus de 40 000 euros à un investisseur !

26/10/16

Managers and Directors - Tobira Therapeutics Inc

Managers	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-0.44%	21.83B
GENMAB A/S	-10.74%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer